Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma.
Hitomi SudoAtsushi B TsujiAya SugyoMika K KanekoYukinari KatoKotaro NagatsuHisashi SuzukiTatsuya HigashiPublished in: Cells (2021)
Alpha-RIT with the newly developed NZ-16 is a promising therapeutic option for malignant mesothelioma.